Exploring the role of different drug transport routes in permeability screening.

Center of Pharmaceutical Informatics, Department of Pharmacy, Uppsala University, Uppsala Biomedical Center, P.O. Box 580, SE-751 23 Uppsala, Sweden.
Journal of Medicinal Chemistry (Impact Factor: 5.61). 02/2005; 48(2):604-13. DOI: 10.1021/jm049711o
Source: PubMed

ABSTRACT The influence of different drug transport routes in intestinal drug permeability screening assays was studied. Three experimental models were compared: the small-intestine-like 2/4/A1 cell model, which has a leaky paracellular pathway, the Caco-2 cell model, which has a tighter paracellular pathway, and artificial hexadecane membranes (HDMs), which exclusively model the passive transcellular pathway. The models were investigated regarding their ability to divide passively and actively transported compounds into two permeability classes and to rank compounds according to human intestinal absorption. In silico permeability models based on two-dimensional (2D) and three-dimensional (3D) molecular descriptors were also developed and validated using external test sets. The cell-based models classified 80% of the acceptably absorbed compounds (FA >/= 30%) correctly, compared to 60% correct classifications using the HDM model. The best compound ranking was obtained with 2/4/A1 (r(s) = 0.74; r(s) = 0.95 after removing actively transported outliers). The in silico model based on 2/4/A1 permeability gave results of similar quality to those obtained when using experimental permeability, and it was also better than the experimental HDM model at compound ranking (r(s) = 0.85 and 0.47, respectively). We conclude that the paracellular transport pathway present in the cell models plays a significant role in models used for intestinal permeability screening and that 2/4/A1 in vitro and in silico models are promising alternatives for drug discovery permeability screening.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oral drug administration can be problematic owing to the specific physicochemical characteristics of new chemical entities. Assessment of the possibility of a new active compound to be administered orally, as well as of the requirements for a successful oral administration (type of dosage form, dosing conditions), constitute a substantial burden during the drug-discovery and drug-development process. Throughout drug development, in silico, in vitro, in vivo and integrated dynamic models play an important role for the decision making in absorption-related issues. In this review, the most common methods used for the prediction of oral drug absorption as a stage development approach are discussed.
    Expert Review of Clinical Pharmacology 02/2009; 2(2):195-208.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adequate permeability is essential for good oral absorption and proper interpretation of pharmacokinetic and pharmacological data. Permeability-limiting absorption and distribution, however, are complex phenomena involving multiple mechanisms and organs ranging from gastro-intestine, liver, kidney to BBB, while the options for pharmaceutical improvement of permeability are quite limited. In this article, the comprehensive in silico, in vitro and in vivo/ex vivo/in situ tools to assess permeability are reviewed, alongside their advantages and limitations. Several key points relating to the in vivo predictive impact of in vitro permeability tools and the caveats when dealing with challenging discovery compounds were also addressed, using drug discovery cases and statistics in Novartis. The integrated strategy to properly utilize existing permeability tools for mitigating the permeability-related absorption or safety risks at the different stages of drug discovery and development processes is presented. It is critical to utilize the comprehensive in silico, in vitro and in vivo/ex vivo tools to dial out permeability issues in early drug discovery, ensuring the right questions to be addressed using the right tools at the right time.
    Expert Opinion on Drug Metabolism &amp Toxicology 02/2010; 6(2):171-87. · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a growing need for highly accurate in silico and in vitro predictive models to facilitate drug discovery and development. Results from in vitro permeation studies across the Caco-2 cell monolayer are commonly used for drug permeability screening in industry and are also accepted as a surrogate for human intestinal permeability measurements by the US FDA to support new drug applications. Countless studies carried out in this cell line with published permeability measurements have enabled the development of many in silico prediction models. We identify several common cases that illustrate how using Caco-2 permeability measurements in these in silico and in vitro predictive models will not correlate with human intestinal permeability and will further lead to inaccuracies in these models. We provide guidelines and recommendations for improving these models to more accurately predict clinically relevant information, thereby enhancing the drug discovery, development, and regulatory approval processes.
    The AAPS Journal 01/2013; · 4.39 Impact Factor